Skip to main content
Fig. 4 | Cancer Nanotechnology

Fig. 4

From: Anticancer platinum-drug delivered by mesenchymal stromal cells improves its activity on glioblastoma

Fig. 4

In vitro activity of secretome and cell lysates from AT-MSCs loaded with Pt-8AQ 12,5 µM on U87-MG. A Pt-8AQ loaded by AT-MSCs upon 1 h of treatment with 12.5 µM of drug (cell LYS) and secreted in the medium upon 48 h of incubation (secretome), expressed by pg of drug per cell. B Activity of free drug, secretome and cell lysate on the proliferation of U87-MG. Data are expressed as percentage of cell growth normalized on the effect of secretome or lysate released by untreated AT-MSCs used as controls. Dotted lines represent linear regression of each curve. C Values of IC50 found for PT-8AQ, secretome, and lysates expressed in ng/ml of drug. In each graph, data are reported as the mean ± standard error of at least three independent experiments. (*p < 0.001)

Back to article page